SCHEMBL2484995

SCHEMBL2484995

CC(C)(NC(=O)c1ccc(C(F)(F)F)cc1)C(=O)Nc1nc(-c2ccccc2)c(Cc2ccccc2)s1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLTP P55058 6/20 0.51
RORC P51449 2/20 0.48
DGAT1 O75907 2/20 0.45
NPC1 O15118 2/20 0.42
KMT2A Q03164 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
DHODH Q02127 1/20 0.42
ALDH1A1 P00352 2/20 0.42
PTGDR2 Q9Y5Y4 2/20 0.42
PPARD Q03181 1/20 0.41
PPARA Q07869 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2485677 0.90 PLTP (0.51) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2487641 0.90 DGAT1 (0.49) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2487621 0.89 PLTP (0.49) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2318436 0.89 PLTP (0.50) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2316339 0.89 RORC (0.47) PLTPRORCDGAT1DHODHALDH1A1
SCHEMBL2487852 0.88 RORC (0.49) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2488081 0.88 PLTP (0.50) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2491014 0.88 ADORA1 (0.55) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2490168 0.88 PLTP (0.51) PLTPRORCDGAT1NPC1KMT2A
SCHEMBL2487360 0.86 DGAT1 (0.63) PLTPRORCDGAT1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703761-B2 Organic compounds NOVARTIS AG (CH) 2014-04-22 US disclosed
EP-2559455-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2013-02-20 EP disclosed
EP-2548618-A2 Organic compounds Novartis AG (CH) 2013-01-23 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
CN-102119047-A Heteroaryl derivatives as DGAT1 inhibitors NOVARTIS AG 2011-07-06 CN disclosed
US-20100022513-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022513-A1 ORGANIC COMPOUNDS DGAT1, DGAT2, SOAT1 PLTP 575/4885RORC 1166/4885DGAT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.